Research Analysts Offer Predictions for ASMB Q1 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Equities researchers at HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Assembly Biosciences in a note issued to investors on Monday, March 24th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will post earnings per share of ($1.54) for the quarter, up from their previous forecast of ($1.95). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.57) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.05) EPS, FY2027 earnings at ($12.07) EPS and FY2028 earnings at ($12.32) EPS.

A number of other research firms have also weighed in on ASMB. StockNews.com lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Monday. Guggenheim started coverage on Assembly Biosciences in a research report on Tuesday. They set a “buy” rating and a $31.00 price target for the company.

Assembly Biosciences Stock Down 5.3 %

Shares of ASMB opened at $10.81 on Wednesday. The stock has a market capitalization of $68.71 million, a P/E ratio of -1.61 and a beta of 0.62. Assembly Biosciences has a twelve month low of $10.27 and a twelve month high of $19.93. The firm has a fifty day simple moving average of $12.70 and a two-hundred day simple moving average of $15.02.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The firm had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $7.05 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Peapod Lane Capital LLC purchased a new position in shares of Assembly Biosciences in the 4th quarter valued at approximately $994,000. JPMorgan Chase & Co. lifted its position in Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 3,442 shares during the period. FMR LLC lifted its position in Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 3,635 shares during the period. Monimus Capital Management LP bought a new stake in shares of Assembly Biosciences during the 4th quarter valued at $664,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of Assembly Biosciences in the 4th quarter worth about $180,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Insider Activity at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of the stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the acquisition, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.10% of the stock is currently owned by company insiders.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.